Skip to main content
Clinical Trials/NCT05836051
NCT05836051
Completed
Not Applicable

Testing the Effect of ENDS Flavors on Neurotransmission

Milton S. Hershey Medical Center1 site in 1 country36 target enrollmentJune 1, 2023

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Tobacco Dependence
Sponsor
Milton S. Hershey Medical Center
Enrollment
36
Locations
1
Primary Endpoint
Brain reward reactivity
Status
Completed
Last Updated
7 months ago

Overview

Brief Summary

The overarching goal of this translational proposal is to determine if neuroactive flavor chemicals can enhance the addiction potential of electronic nicotine delivery systems (ENDS) by altering brain function and behavior.

Detailed Description

For this randomized double-blind controlled trial, tobacco users will be randomized to use ENDS with an e-liquid containing a neuroactive green-apple flavor (hexyl acetate) vs. an inactive green-apple flavor (ethyl acetate) for ten days as a supplement to their typical tobacco use. Laboratory measures of ENDS reinforcement, subjective ENDS ratings, and brain reactivity to the flavor using functional magnetic resonance imaging (fMRI) will be collected at baseline and after ten days of ENDS use.

Registry
clinicaltrials.gov
Start Date
June 1, 2023
End Date
July 31, 2025
Last Updated
7 months ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Andrea Hobkirk, PhD

Assistant Professor

Penn State University

Eligibility Criteria

Inclusion Criteria

  • 21 years old or older
  • Weekly user of inhaled tobacco products, including inhaled ENDS, nicotine vapes, cigarettes, regular and little cigars for at least last three months
  • Not planning to quit tobacco use within next month
  • Able to read and write in English

Exclusion Criteria

  • Current substance use impairing participation
  • Unstable or significant medical conditions (e.g., COPD, coronary heart disease)
  • Current use of smoking cessation medication (e.g., varenicline, patch)
  • Uncontrolled serious mental illness, suicidality, or inpatient psychiatric hospitalization in the past 6 months
  • Unable or unwilling to abstain from nicotine products for 14 hours prior to the scheduled visit, self-reported.
  • MRI-specific exclusion criteria:
  • MRI safety contraindications (e.g., metal implants, claustrophobia)
  • Major neurological conditions or brain trauma

Outcomes

Primary Outcomes

Brain reward reactivity

Time Frame: Pre to post-intervention (approximately 10 days)

Brain reward reactivity will be calculated as the percent change in average blood oxygen-level dependent (BOLD) signal in a pre-defined ventral tegmental area (VTA) region of interest during ENDS inhalation

Absolute reinforcement

Time Frame: Pre to post-intervention (approximately 10 days)

Absolute reinforcement will be calculated as the change in the average number of puffs per day during a 10-day use period

Study Sites (1)

Loading locations...

Similar Trials